Autologous Bone Marrow Mononuclear Cell Therapy is Safe and Promotes Amputation Free Survival in Patients with Critical Limb Ischemia

OBJECTIVE: The purpose of this phase I open label non-randomized trial was to assess the safety and efficacy of autologous bone marrow mononuclear cell (ABMNC) therapy in promoting amputation free survival (AFS) in patients with critical limb ischemia (CLI). METHODS: Between September 2005 and March...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Murphy, Michael P., Lawson, Jeffrey H., Rapp, Brian M., Dalsing, Michael C., Klein, Janet, Wilson, Michael G., Hutchins, Gary D., March, Keith L.
Formato: Artigo
Idioma:Inglês
Publicado: 2011
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3102148/
https://ncbi.nlm.nih.gov/pubmed/21514773
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jvs.2011.01.074
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares